Novo Nordisk says it is investing about $130 million in new laboratories at the firm's R&D campus in Måløv, Denmark. Construction is already underway for the new facility, called Diabetes Research House, and it should be complete in early 2016.
According to the company, with floor space of 16,500 square meters distributed on three stories, Diabetes Research House will have two laboratory wings, a middle building with office space, and an auditorium seating 450 people. Mads Krogsgaard Thomsen, Ph.D., Novo Nordisk's evp and CSO, said in a statement that the facility will provide an environment for diabetes research within biotechnology and protein chemistry.
"Here [at the facility] our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes," said Thomsen. Read the full release